<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37414530</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Survival in sporadic ALS is associated with lower p62 burden in the spinal cord.</ArticleTitle><Pagination><StartPage>769</StartPage><EndPage>773</EndPage><MedlinePgn>769-773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlad051</ELocationID><Abstract><AbstractText>The autophagy marker p62 appears as a consistent component of pathological aggregates in amyotrophic lateral sclerosis (ALS) and its modulation to facilitate protein degradation has been proposed as a potential therapeutic target. Importantly, recent studies have implicated diffuse phosphorylated TDP-43 inclusions that are immuno-negative for p62 in more rapid disease, highlighting the need for better understanding of p62 involvement in ALS pathogenesis. The present study set out to assess p62 pathology in the motor neurons of 31 patients with sporadic ALS that had either a short (&lt;2&#x2009;years) or longer (4-7&#x2009;years) disease duration to determine its association with pTDP-43 pathology, motor neuron loss, and survival in sporadic disease. Our results identified significantly more cytoplasmic p62 aggregates in the spinal cord of patients with a shorter survival. Disease duration demonstrated a negative association with p62 burden and density of remaining motor neurons in the spinal cord, suggesting that survival in sporadic ALS is associated with the successful clearance of lower motor neurons with p62 aggregates. These findings implicate the autophagy pathway in ALS survival and provide support for further study of p62 as a potential prognostic biomarker in ALS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinkerton</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lourenco</LastName><ForeName>Guinevere</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Maria Torres</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Rachel H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0002-0385-4090</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">p62 pathology</Keyword><Keyword MajorTopicYN="N">pTDP-43</Keyword></KeywordList><CoiStatement>The authors have no duality or conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37414530</ArticleId><ArticleId IdType="pmc">PMC10440721</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlad051</ArticleId><ArticleId IdType="pii">7220740</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan RH, Ke YD, Ittner LM, et al. &#xa0;ALS/FTLD: Experimental models and reality. Acta Neuropathol &#xa0;2017;133:177&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster AD, Rea SL. &#xa0;The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis. Neural Regen Res &#xa0;2020;15:2186&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749485</ArticleId><ArticleId IdType="pubmed">32594029</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson JM, Chung RS, Lee A. &#xa0;The converging roles of sequestosome-1/p62 in the molecular pathways of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Neurobiol Dis &#xa0;2022;166:105653.</Citation><ArticleIdList><ArticleId IdType="pubmed">35143965</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, et al. &#xa0;The frontotemporal dementia-motor neuron disease continuum. Lancet &#xa0;2016;388:919&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. &#xa0;Amyotrophic lateral sclerosis. Lancet &#xa0;2011;377:942&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cathcart SJ, Appel SH, Peterson LE, et al. &#xa0;Fast progression in amyotrophic lateral sclerosis is associated with greater TDP-43 burden in spinal cord. J Neuropathol Exp Neurol &#xa0;2021;80:754&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8433592</ArticleId><ArticleId IdType="pubmed">34383907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon T, Mori F, Tanji K, et al. &#xa0;Accumulation of nonfibrillar TDP-43 in the rough endoplasmic reticulum is the early-stage pathology in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol &#xa0;2022;81:271&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">35294549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumder S, Kiernan MC, Halliday GM, et al. &#xa0;The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review. Neuropathol Appl Neurobiol &#xa0;2022;48:e12845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9804699</ArticleId><ArticleId IdType="pubmed">35921237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, et al. &#xa0;TDP-43 proteinopathies: Pathological identification of brain regions differentiating clinical phenotypes. Brain &#xa0;2015;138:3110&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. &#xa0;Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol &#xa0;2013;74:20&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ludolph AB, Neumann M, et al. &#xa0;Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal alpha-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol &#xa0;2017;133:79&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209403</ArticleId><ArticleId IdType="pubmed">27757524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Baer GM, et al. &#xa0;Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol &#xa0;2017;134:65&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, et al. &#xa0;Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol &#xa0;2008;64:60&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, et al. &#xa0;Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol &#xa0;2009;117:137&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortnik S, Gorski SM. &#xa0;Clinical applications of autophagy proteins in cancer: From potential targets to biomarkers. Int J Mol Sci &#xa0;2017;18:1496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5535986</ArticleId><ArticleId IdType="pubmed">28696368</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaudin de The FX, Lassus B, Schaler AW, et al. &#xa0;p62 accumulates through neuroanatomical circuits in response to tauopathy propagation. Acta Neuropathol Commun &#xa0;2021;9:177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8561893</ArticleId><ArticleId IdType="pubmed">34727983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Attarwala IY, Xie XQ. &#xa0;SQSTM1/p62: A potential target for neurodegenerative disease. ACS Chem Neurosci &#xa0;2019;10:2094&#x2013;114</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712989</ArticleId><ArticleId IdType="pubmed">30657305</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster AD, Flynn LL, Cluning C, et al. &#xa0;p62 overexpression induces TDP-43 cytoplasmic mislocalisation, aggregation and cleavage and neuronal death. Sci Rep &#xa0;2021;11:11474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8169680</ArticleId><ArticleId IdType="pubmed">34075102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuusisto E, Salminen A, Alafuzoff I. &#xa0;Early accumulation of p62 in neurofibrillary tangles in Alzheimer&#x2019;s disease: Possible role in tangle formation. Neuropathol Appl Neurobiol &#xa0;2002;28:228&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">12060347</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnick ND, Griffey CJ, Guarnieri P, et al. &#xa0;Distinct roles for motor neuron autophagy early and late in the SOD1(G93A) mouse model of ALS. Proc Natl Acad Sci USA &#xa0;2017;114:E8294&#x2013;303</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5625902</ArticleId><ArticleId IdType="pubmed">28904095</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdelski C, Reiswich V, Hube-Magg C, et al. &#xa0;Cytoplasmic accumulation of sequestosome 1 (p62) is a predictor of biochemical recurrence, rapid tumor cell proliferation, and genomic instability in prostate cancer. Clin Cancer Res &#xa0;2015;21:3471&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">25925890</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue D, Suzuki T, Mitsuishi Y, et al. &#xa0;Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci &#xa0;2012;103:760&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7659245</ArticleId><ArticleId IdType="pubmed">22320446</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo RZ, Yuan ZY, Li M, et al. &#xa0;Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Onco Targets Ther &#xa0;2013;6:883&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722135</ArticleId><ArticleId IdType="pubmed">23888115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolland P, Madjd Z, Durrant L, et al. &#xa0;The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer &#xa0;2007;14:73&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pubmed">17395976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlafli AM, Adams O, Galvan JA, et al. &#xa0;Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget &#xa0;2016;7:39544&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5129952</ArticleId><ArticleId IdType="pubmed">27250032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino E, Boschi S, Roveta F, et al. &#xa0;Investigating p62 concentrations in cerebrospinal fluid of patients with dementia: A potential autophagy biomarker in vivo? &#xa0;Brain Sci &#xa0;2022;12:1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9599226</ArticleId><ArticleId IdType="pubmed">36291347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>